Characteristics and outcome of type 2 diabetes in urban Aboriginal people [3]

Internal Medicine Journal

Volumn 37, Issue 8, 2007, Pages 581-582

  Morton, A P ^a  

^a MATER ADULT HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

GLICLAZIDE; GLIMEPIRIDE; GLITAZONE DERIVATIVE; INSULIN; INSULIN GLARGINE; METFORMIN; SULFONYLUREA DERIVATIVE;

ABORIGINE; AUSTRALIA; CONTROLLED STUDY; DISEASE DURATION; DRUG EFFICACY; ETHNIC DIFFERENCE; FEMALE; HEALTH CARE AVAILABILITY; HUMAN; INSULIN TREATMENT; LETTER; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT ATTITUDE; PRIORITY JOURNAL; TREATMENT OUTCOME;

DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; OCEANIC ANCESTRY GROUP; PATIENT COMPLIANCE; URBAN HEALTH; WESTERN AUSTRALIA;

EID: 34447513165     PISSN: 14440903     EISSN: 14455994     Source Type: Journal    
DOI: 10.1111/j.1445-5994.2007.01414.x     Document Type: Letter

References (3)

1. Davis TME, McAullay D, Davis WA, Bruce DG. Characteristics and outcome of type 2 diabetes in urban Aboriginal people: the Fremantle diabetes study. Intern Med J 2007 37:59 63.
2. Aljabri K, Kozak SE, Thompson DM. Addition of pioglitazone or bedtime insulin to maximal doses of sulfonylurea and metformin in type 2 diabetes patients with poor glucose control: a prospective, randomized trial. Am J Med 2004 116:230 35.
3. Rosenstock J, Sugimoto D, Strange P, Stewart JA, Soltes-Rak E, Dailey G. Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naïve patients. Diabetes Care 2006 29:554 9.